Furthermore, alectinib was recently shown to be more effective and less toxic than crizotinib in treating ALK-positive NSCLC as a first line therapy, demonstrating a 12-month event-free survival rate of 68.4% in comparison to 48.7% with crizotinib [38]. Here, ALK is linked to non-small cell lung carcinoma.